Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
-
Published:2021-11
Issue:
Volume:157
Page:153-164
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
de la Fouchardière ChristelleORCID,
Godbert Yann,
Dalban Cécile,
Illouz Frédéric,
Wassermann Johanna,
Do Cao Christine,
Bardet StéphaneORCID,
Zerdoud Slimane,
Chougnet Cécile N.ORCID,
Zalzali Mohamed,
Benisvy Danielle,
Niccoli Patricia,
Digue Laurence,
Lamartina LiviaORCID,
Schwartz Paul,
Borson Chazot FrançoiseORCID,
Gautier Julien,
Pérol David,
Leboulleux SophieORCID
Subject
Cancer Research,Oncology
Reference34 articles.
1. Refractory thyroid cancers;Schlumberger;Presse Med,2011
2. WHO classification of tumours of endocrine organs;Lloyd,2017
3. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery;Zerdoud;Ann Endocrinol (Paris),2017
4. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer;Haugen;Thyroid,2016
5. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed?;Haugen;Cancer,2017
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献